This open-label, multicenter, phase 1B/2 trial evaluated the efficacy, safety, tolerability, biologic activity, and pharmacokinetic profile of AUY922 in combination with trastuzumab in patients with locally advanced or metastatic HER2-positive breast cancer previously treated with chemotherapy and anti-HER2 therapy. Here, ERBB2 is linked to breast carcinoma.